27 March 2020
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.
5 December 2019
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.
24 June 2019
PBS features Daniel O'Connor's research on how children's genetic profiles affect their immunity.
23 April 2019
Drs Samantha Vanderslott and Claas Kirchhelle introduce their typhoid history research and 'Alice in Typhoidland' public engagement project. This work delves into the history of typhoid in Oxford and highlights why typhoid is still a major global health problem needing both water, sanitation, and hygiene (WASH) interventions alongside vaccines.
16 July 2018
Dr Matthew Snape leads a study investigating if giving small amounts of oral insulin to babies can prevent type 1 diabetes, thus allowing mothers to protect their children from injecting insulin.
10 July 2018
The National Health Service named Oxford Vaccine Group’s Meningitis B vaccination programme one of the 70 most transformative discoveries over the past 70 years.
18 April 2018
On November 20, 2017, the Typhoid Vaccine Acceleration Consortium (TyVAC) vaccinated the first of 20,000 children against typhoid, successfully launching a study to assess the impact of typhoid conjugate vaccines (TCVs) in preventing typhoid among children in Nepal.
28 March 2018
Researchers are working with schools around the county to find 24,000 volunteers aged 16 to 18 years to take part in the Be on the TEAM (Teenagers Against Meningitis) trial, led by the Oxford Vaccine Group at the Oxford University's Paediatrics Department with funding and support from the National Institute for Health Research (NIHR).
28 March 2018
The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom. Teenagers at participating schools are being asked to take part by local research teams involved.
28 February 2018
Mildred Iro, a Paediatric Research Fellow working with the Oxford Vaccine Group, won the Lorber Prize for the best paediatric publication of 2017 for her work on childhood encephalitis admissions.
4 October 2017
A new technique allowing drugs or vaccines to be encapsulated within tiny biodegradable particles could see an end booster jabs
3 October 2017
The Oxford Safer Pregnancy Alliance [OSPREA] and the Oxford Vaccine Group [OVG] have recently undertaken a successful recruitment drive for a study of maternal immunisation to prevent infant Respiratory Syncytial Virus [RSV] infection.
2 October 2017
Hannah Robinson and Sarah Loving from the Department of Paediatrics were recognised in the annual awards hosted by the Thames Valley Clinical Research Network
29 September 2017
Byline: Andrew Pollard and Katherine Theiss-Nyland, Oxford Vaccine Group, Oxford University
29 August 2017
Respiratory Syncytial Virus (RSV) is one of the most common reasons for young infants to be admitted to hospital, and globally is second only to malaria as a cause of death in infants between 1 and 12 months of age. In the UK it mostly occurs from October to February, causing a wave of infections that stretch the capacity of children’s wards to their limits.
30 March 2017
The Oxford Vaccine Group, part of University of Oxford, gave 99 volunteers a drink laced with live Salmonella Typhi bacteria a month after vaccinating them. Between 40% and 50% of the volunteers for the trial were students, Healthcare professionals were allowed to take part if they were not in patient-facing jobs or if they were willing to take around 3-4 weeks off work to be infected